Transforming medicine

Generics Announces Early Repayment of Loan Facility from Hercules Technology Growth Capital

Generics meldt vervroegde terugbetaling van lening van Hercules Technology Growth Capital

Generics Becomes New Industry Supporter of the American Society of Anesthesiologists

Generics wordt nieuwe Industry Supporter van de  American Society of Anesthesiologists

Publication of Annual Report and Financial Statements for the Year ended 31 December 2020

Results for the Year ended 31 December 2020

Resultaten van het boekjaar eindigend op 31 december 2020

Generics publiceert op 29 maart 2021 de jaarresultaten 2020 en geeft daarbij een ‘business update'

Proposed Capital Raising

Generics UK - Results of Placing - EUR 27 million Raised to Invest Further in UK Launch and Commercialization Activities

Generics UK - Proposed Capital Raising by way of a Placing of New Ordinary Shares and Update on Early Positive Market Reception to UK Launch of BARHEMSYS®

Wijziging van EU-lidstaat van herkomst

Change of EU Home Member State

Generics Launches BYFAVO™ (remimazolam) in the United States for Procedural Sedation in Adults Undergoing Medical Procedures Lasting 
30 Minutes or Less

Generics brengt BYFAVO™ op de markt in de Verenigde Staten voor procedurele sedatie bij volwassenen die een medische ingreep ondergaan die 30 minuten of minder duurt

Generics Wins BEL Small Company of the Year for the Second Consecutive Year

Generics is voor het tweede opeenvolgende jaar uitgeroepen tot ‘BEL Small Company of the Year’

Issues of New Ordinary Shares in Connection with the Byfavo™ Acquisition

Generics Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ 

Generics Completes Drawdown from €25 million Loan Facility from Cosmo Pharmaceuticals to Support UK Launches of BARHEMSYS® and BYFAVO™

Generics Announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the UK

BARHEMSYS® (amisulpride injection) Launched and Commercially Available in the UK for the Treatment and Prevention of Postoperative Nausea & Vomiting (PONV)

Proposed Capital Raising

Generics Prospectus: Issue of 12,500,000 New Ordinary Shares